Patents by Inventor Scott C. Malcolm

Scott C. Malcolm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triple reuptake inhibitors and methods of their use
    Patent number: 10428021
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 1, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20180148407
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 31, 2018
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Triple reuptake inhibitors and methods of their use
    Patent number: 9850204
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: December 26, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20160221947
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Application
    Filed: September 10, 2015
    Publication date: August 4, 2016
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Triple reuptake inhibitors and methods of their use
    Patent number: 9133117
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: September 15, 2015
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20140107175
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit re-uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 17, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Liming SHAO, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Triple reuptake inhibitors and methods of their use
    Patent number: 8592608
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: November 26, 2013
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20110313013
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Application
    Filed: December 15, 2009
    Publication date: December 22, 2011
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Treatment of osteoporosis and autoimmune disease with astrogorgiadiol
    Patent number: 7345035
    Abstract: The invention provides methods of downregulating mRNA encoding osteopontin comprising administering to a cell or mammal an amount of astrogorgiadiol effective to downregulate production of mRNA encoding osteopontin. The invention also provides methods of treating osteoporosis and autoimmune disease comprising administering to a patient in need of such treatment a therapeutically effective amount of astrogorgiadiol. Pharmaceutical compositions comprising astrogorgiadiol and a pharmaceutically acceptable carrier or diluent are also provided.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: March 18, 2008
    Assignee: University of Delaware
    Inventors: Douglass F. Taber, Mary C. Farach-Carson, Scott C. Malcolm, Yihuan Xu
  • Treatment of osteoporosis and autoimmune disease with astrogorgiadiol
    Publication number: 20040242677
    Abstract: The invention provides methods of downregulating mRNA encoding osteopontin comprising administering to a cell or mammal an amount of astrogorgiadiol effective to downregulate production of mRNA encoding osteopontin. The invention also provides methods of treating osteoporosis and autoimmune disease comprising administering to a patient in need of such treatment a therapeutically effective amount of astrogorgiadiol. Pharmaceutical compositions comprising astrogorgiadiol and a pharmaceutically acceptable carrier or diluent are also provided.
    Type: Application
    Filed: May 28, 2003
    Publication date: December 2, 2004
    Inventors: Douglass F. Taber, Mary C. Farach-Carson, Scott C. Malcolm, Yihuan Xu